Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133623 | 0.89 | KMT2A (0.76) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL5374862 | 0.86 | KMT2A (1.00) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL26112506 | 0.86 | KMT2A (0.61) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL7162806 | 0.84 | KMT2A (0.70) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL11132201 | 0.84 | KMT2A (0.70) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL5929617 | 0.84 | KMT2A (0.70) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL12368437 | 0.82 | HDAC1 (0.74) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL12252575 | 0.82 | KMT2A (0.68) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL22060038 | 0.82 | EPHX2 (0.57) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL5357067 | 0.82 | KMT2A (0.68) | KMT2AHDAC1HDAC6ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478057-A | Preparation method of fluororalrana intermediate | 洛阳惠中兽药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1029851-B1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2005-04-20 | — | — | EP | disclosed |
| CN-1145609-C | Piperazine compounds and medical use thereof | ������ҩ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| CN-1281438-A | Piperazine compounds and their use as pharmaceuticals | EFUKU CO LTD (JP) | 2001-01-24 | — | — | CN | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | KMT2A 2109/4885HDAC1 428/4885HDAC6 1002/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | KMT2A 2049/4885HDAC1 438/4885HDAC6 965/4885 |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | TNF, CCR10, RELA | KMT2A 1815/4885HDAC1 507/4885HDAC6 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.